Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The potential impact of biosimilars in hematology

Robin Foà, MD from the Sapienza University, Rome, Italy gives an overview of the session on ‘Biosimilars: shaping the future of Hematology’ held at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Foà discusses how advancements in therapy are impacting on the prognosis of various cancers and, in this context, the problems associated with an aging society. He then talks about drug costs and the issue of access to novel drugs. According to Prof. Foà, biosimilars may help reduce costs and increase access to drugs.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.